Watch BTCY. Know when insiders buy.
One email the day a filing lands. Free.
BTCY
BIOTRICITY INC.
0.09
−0.01 −10.00%
USD · close Sep 8
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
53
WATCH · shorts 53
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.8MP/E —DIV YIELD —FCF YIELD —REV TTM $16.4M +13.4%NET INCOME −$2.7MNET CASH —52W 0.09 – 0.73SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 2027 · Jun 30 | $4.3M | +10.4% | 82.6% | $158K | −$959K | — | -0.05 | $507K | — | — | Aug 19 |
| Q4 2026 · Mar 31derived | $4.3M | +14.8% | 80.0% | $695K | −$324K | — | -0.02 | −$21K | — | — | Jul 14 |
| Q3 2026 · Dec 31 | $4M | +10.2% | 81.5% | $441K | −$717K | — | -0.04 | −$740K | — | — | Feb 11 |
| Q2 2026 · Sep 30 | $3.9M | +18.9% | 81.9% | $274K | −$691K | — | -0.03 | $416K | — | — | Nov 14 |
| Q1 2026 · Jun 30 | $3.9M | +21.0% | 80.5% | $282K | −$672K | — | -0.03 | −$373K | — | — | Aug 19 |
| Q4 2025 · Mar 31derived | $3.7M | +16.5% | 80.4% | −$855K | −$1.9M | — | -0.06 | −$401K | — | — | Jul 14 |
| Q3 2025 · Dec 31 | $3.6M | +21.7% | 76.4% | −$169K | −$1.2M | — | -0.05 | −$88K | — | — | Feb 11 |
| Q2 2025 · Sep 30 | $3.3M | +13.0% | 75.3% | −$308K | −$1.6M | — | -0.07 | −$397K | — | — | Nov 14 |
| Q1 2025 · Jun 30 | $3.2M | — | 73.8% | −$1.1M | −$3.7M | — | -0.49 | −$1.5M | — | — | Aug 14 |
| Q4 2024 · Mar 31derived | $3.2M | — | 71.5% | −$3M | −$4.2M | — | -0.47 | −$1.2M | — | — | Jul 18 |
| Q3 2024 · Dec 31 | $3M | — | 72.9% | −$1.3M | −$2.8M | — | -0.34 | −$1.3M | — | — | Feb 20 |
| Q2 2024 · Sep 30 | $2.9M | — | 69.1% | −$2.2M | −$3.7M | — | -0.44 | −$2.4M | — | — | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2026 · to Mar 31 | $16M | 80.9% | $1.7M | −$2.4M | -15.0% | -0.12 | −$719K | — | — | — | — |
| FY2025 · to Mar 31 | $13.8M | 76.6% | −$2.4M | −$8.4M | -61.1% | -0.56 | −$2.4M | — | — | — | — |
| FY2024 · to Mar 31 | $12.1M | 69.3% | −$8.8M | −$14.1M | -116.8% | -1.66 | −$6.7M | — | — | — | — |
| FY2023 · to Mar 31 | $9.6M | 56.5% | −$15.4M | −$18.7M | -193.6% | -2.26 | −$13.5M | — | — | — | — |
| FY2022 · to Mar 31 | $7.7M | 59.7% | −$16.7M | −$29.1M | -380.8% | -0.67 | −$15.2M | $30K | −$15.2M | — | — |
| FY2021 · to Mar 31 | $3.4M | 37.6% | — | −$15.5M | -457.7% | -0.44 | −$11.1M | — | — | — | $603K |
Every number comes from BIOTRICITY INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.